Want to see TSE:XTRX full AI Analyst Report?
XTRX Stock Chart & Stats
C$0.20
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.20
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.20 - C$0.40
Previous CloseN/A
Volume1.65K
Average Volume (3M)323.00
Market Cap
C$1.12M
Enterprise ValueC$4.56
Total Cash (Recent Filing)C$786.60K
Total Debt (Recent Filing)C$3.57M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding5,597,050
10 Day Avg. Volume51
30 Day Avg. Volume323
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)8.69
Price to Sales (P/S)0.51
P/FCF Ratio30.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized B2B Extraction And FormulationAdastra Labs operates a focused, specialty business supplying refined cannabinoid ingredients to manufacturers. That B2B ingredient model is durable: it relies on production know-how and contract relationships rather than retail foot traffic, supporting steady demand from downstream brands and potential for long-term supply agreements.
Diversified End-market Exposure (consumer & Medical)Serving both consumer and medical product manufacturers gives the company structurally broader demand drivers. Exposure across therapeutic and consumer segments reduces reliance on any single product cycle and can smooth revenue volatility over time as different end markets respond differently to regulation and consumer trends.
Moderate Gross Profit Margin On Core ProcessingA mid-30% gross margin indicates the core extraction and formulation process has reasonable unit economics. Even though operating profitability is currently negative, this gross margin suggests there is a structural ability to generate production-level profit that could flow to the bottom line with tighter operating expense control or scale improvements.
Bears Say
Declining Revenue And Large LossesRevenues are declining materially while net margins are deeply negative, indicating the business is shrinking while losing cash on sales. Sustained top-line contraction combined with heavy losses undermines scale economics, limits reinvestment capacity, and makes achieving a durable turnaround more difficult without clear demand or margin recovery.
Negative Equity And Solvency RiskNegative shareholder equity and an extreme debt-to-equity ratio signal structural balance-sheet weakness and potential solvency stress. This reduces financial flexibility, increases refinancing risk, and can constrain investment or growth initiatives, forcing management to prioritize capital restructuring over strategic opportunities.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flows show the company is burning cash from core operations. Persistent cash deficits limit the ability to fund working capital, R&D, or capex internally and increase dependence on external financing, which may be costly or unavailable given the weak balance sheet and operating losses.
Adastra Labs Holdings Ltd. News
XTRX FAQ
What was Adastra Labs Holdings Ltd.’s price range in the past 12 months?
Adastra Labs Holdings Ltd. lowest stock price was C$0.20 and its highest was C$0.40 in the past 12 months.
What is Adastra Labs Holdings Ltd.’s market cap?
Adastra Labs Holdings Ltd.’s market cap is C$1.12M.
When is Adastra Labs Holdings Ltd.’s upcoming earnings report date?
Adastra Labs Holdings Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 15 days.
How were Adastra Labs Holdings Ltd.’s earnings last quarter?
Currently, no data Available
Is Adastra Labs Holdings Ltd. overvalued?
According to Wall Street analysts Adastra Labs Holdings Ltd.’s price is currently Overvalued.
Does Adastra Labs Holdings Ltd. pay dividends?
Adastra Labs Holdings Ltd. does not currently pay dividends.
What is Adastra Labs Holdings Ltd.’s EPS estimate?
Adastra Labs Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adastra Labs Holdings Ltd. have?
Adastra Labs Holdings Ltd. has 5,597,050 shares outstanding.
What happened to Adastra Labs Holdings Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adastra Labs Holdings Ltd.?
Currently, no hedge funds are holding shares in TSE:XTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adastra Labs Holdings Ltd.
Adastra Holdings Ltd. is a company specializing in solutions for cannabis processing and extraction. It provides a variety of services, including comprehensive analytical testing and processing for cannabis. The company offers its processing expertise to licensed cultivators of both cannabis and hemp. Additionally, it supplies cannabis extracts to qualified business-to-business partners, serving both Canadian and international markets. Formed in 1987, Adastra Holdings Ltd. adopted its current name in September 2021, having previously been known as Phyto Extractions Inc. The company's headquarters are located in Langley, Canada.